Home / Health / Moderna's Cancer Vaccine: A New Hope
Moderna's Cancer Vaccine: A New Hope
20 Aug
Summary
- Experimental melanoma vaccine shows significant patient improvement.
- Treatment combines personalized mRNA vaccine with Keytruda.
- Trial data suggests longer cancer-free periods for patients.
Moderna announced a significant advancement in its experimental melanoma treatment, suggesting its personalized mRNA vaccine could be key in preventing the deadly skin cancer's return. This development emerged from a Phase 3 clinical trial involving over 1,100 individuals with advanced melanoma.
The innovative vaccine is built using a patient's own tumor. Advanced analysis identifies unique mutations, and artificial intelligence helps select the most critical ones for the vaccine. This personalized mRNA shot works in tandem with Merck's immunotherapy drug, Keytruda.
Keytruda acts by removing a protective 'cloak' that cancer cells use to evade the immune system. Subsequently, the synthetic mRNA from Moderna's vaccine trains the immune system to recognize and attack remaining cancer cells, akin to a bloodhound following a scent.
Results from the trial indicated that patients treated with the combination of Moderna's vaccine and Keytruda, following surgical tumor removal and standard Keytruda treatment, remained cancer-free for longer periods. Melanoma is a prevalent cancer in the U.S., with tens of thousands of new cases annually.
